{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:41:02Z","timestamp":1778625662037,"version":"3.51.4"},"reference-count":27,"publisher":"Media Sphere Publishing House","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Bull. Otorhino."],"published-print":{"date-parts":[[2023,9,28]]},"abstract":"<jats:p>Chronic rhinosinusitis (CRS) with nasal polyps is the most severe form of inflammatory diseases of the paranasal sinuses, especially in combination with comorbid asthma. A new avenue for the personalized treatment of severe forms of eosinophilic inflammation are biologics based on humanized monoclonal antibodies. Objective. To study the effectiveness of targeted therapy in patients with CRS with nasal polyps and comorbid asthma. Material and methods. 19 patients selected for biological therapy according to international criteria were studied. The patients were randomly divided into 2 groups. The first group included 10 patients treated with dupilumab. Dupilumab was administered subcutaneously 300 mg every 2 weeks for 24 weeks. Group 2 included 9 patients treated with reslizumab for severe eosinophilic asthma with comorbid CRS with nasal polyps. Reslizumab was administered intravenously 3 mg\/kg body weight once every 4 weeks for 24 weeks. These patients constituted the comparison group. Both drugs are used in treatment of eosinophilic inflammation but have different biological targets. Results. Comparative analysis of the dynamics of the main indicators characterizing the clinical course of CRS with nasal polyps and asthma (SNOT-22, control of asthma symptoms \u2014 ACT, the results of SCT of the paranasal sinuses according to the Lund-Mackay score) revealed a positive trend in patients of both groups, more pronounced in patients receiving dupilumab. Conclusion. Changes in CT of the paranasal sinuses, characterized by the Lund-Mackay score, the results of SNOT-22 and ACT are the most demonstrative and can be used to assess the results of treatment with biologics in patients with chronic rhinosinusitis with nasal polyps.<\/jats:p>","DOI":"10.17116\/otorino20228804146","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T08:11:46Z","timestamp":1695888706000},"page":"46","source":"Crossref","is-referenced-by-count":4,"title":["Experience with dupilumab in the treatment of chronic rhinosinusitis with nasal polyps"],"prefix":"10.17116","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-5061","authenticated-orcid":false,"given":"N.V.","family":"Boiko","sequence":"first","affiliation":[{"name":"Rostov State Medical University of the Ministry of Health of Russia","place":["Rostov-on-Don, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-2062","authenticated-orcid":false,"given":"I.V.","family":"Stagnieva","sequence":"additional","affiliation":[{"name":"Rostov State Medical University of the Ministry of Health of Russia","place":["Rostov-on-Don, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-0680","authenticated-orcid":false,"given":"O.E.","family":"Lodochkina","sequence":"additional","affiliation":[{"name":"Rostov State Medical University of the Ministry of Health of Russia","place":["Rostov-on-Don, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2343-734X","authenticated-orcid":false,"given":"N.V.","family":"Kurbatova","sequence":"additional","affiliation":[{"name":"Southern Federal University","place":["Rostov-on-Don, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/otorino20228804146-1","doi-asserted-by":"publisher","DOI":"10.17116\/otorino20228701181"},{"key":"key-10.17116\/otorino20228804146-2","doi-asserted-by":"publisher","DOI":"10.4193\/rhin17.255"},{"key":"key-10.17116\/otorino20228804146-3","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21847"},{"key":"key-10.17116\/otorino20228804146-4","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26391"},{"key":"key-10.17116\/otorino20228804146-5","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-019-0269-4"},{"key":"key-10.17116\/otorino20228804146-6","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22487"},{"key":"key-10.17116\/otorino20228804146-7","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21739"},{"key":"key-10.17116\/otorino20228804146-8","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22214"},{"key":"key-10.17116\/otorino20228804146-9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"key-10.17116\/otorino20228804146-10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.03.007"},{"key":"key-10.17116\/otorino20228804146-11","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.600"},{"key":"key-10.17116\/otorino20228804146-12","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2021.1937132"},{"key":"key-10.17116\/otorino20228804146-13","doi-asserted-by":"publisher","DOI":"10.1111\/imj.67_13578"},{"key":"key-10.17116\/otorino20228804146-14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0702-4"},{"key":"key-10.17116\/otorino20228804146-15","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221105749"},{"key":"key-10.17116\/otorino20228804146-16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"key-10.17116\/otorino20228804146-17","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.01.012"},{"key":"key-10.17116\/otorino20228804146-18","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22780"},{"key":"key-10.17116\/otorino20228804146-19","doi-asserted-by":"publisher","DOI":"10.20969\/VSKM.2021.14(6).22-27"},{"key":"key-10.17116\/otorino20228804146-20","doi-asserted-by":"publisher","DOI":"10.1111\/all.13875"},{"key":"key-10.17116\/otorino20228804146-21","doi-asserted-by":"crossref","unstructured":"Kim J, Naclerio R. Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date. Therapeutics and Clinical Risk Management. 2020;16:31-37","DOI":"10.2147\/TCRM.S210648"},{"key":"key-10.17116\/otorino20228804146-22","doi-asserted-by":"publisher","DOI":"10.17116\/otorino20218602143"},{"key":"key-10.17116\/otorino20228804146-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.08.021"},{"key":"key-10.17116\/otorino20228804146-24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"key-10.17116\/otorino20228804146-25","unstructured":"Kurbatova NV. Paket STATISTICA, analiz dannykh i vyyavlenie zakonomernostei. TsVVR; 2002. (In Russ.)"},{"key":"key-10.17116\/otorino20228804146-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.01.013"},{"key":"key-10.17116\/otorino20228804146-27","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s243053"}],"container-title":["Russian Bulletin of Otorhinolaryngology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T14:07:56Z","timestamp":1745503676000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-otorinolaringologii\/2023\/4\/1004246682023041046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,9,28]]}},"alternative-id":["10.17116\/otorino20228804146"],"URL":"https:\/\/doi.org\/10.17116\/otorino20228804146","relation":{},"ISSN":["0042-4668"],"issn-type":[{"value":"0042-4668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}